Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 24, 2016
Pharmacy Choice - News - Pharmaceutical Development - May 24, 2016

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/24/16 - Seqirus Gets FDA Approval For Flucelvax Quadrivalent For 4 Yrs Of Age And Older
BASEL- Seqirus, part of CSL Limited, said that the US Food and Drug Administration has approved Flucelvax Quadrivalent or Influenza Vaccine, the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older.FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B virus
5/24/16 - Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT? (Influenza Vaccine) for people four years of age and older
Seqirus announced today that the US Food and Drug Administration has approved FLUCELVAX QUADRIVALENT?, the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. 1,2 FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World H
5/23/16 - Acer Therapeutics Closes $8.15 Million Series B Financing
By a News Reporter-Staff News Editor at Pharma Business Week Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, announced the company has closed its Series B round with $8.15 million in new investment. Luc Marengere, Managing Partner of TVM Life Science Capital, joi
5/23/16 - Advanced Accelerator Applications preparing for Lutathera launch by scaling up production in Ivrea, Italy
AAA has recently submitted a New Drug Application to the US Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for its lead Neuro Endocrine Tumor therapeutic candidate Lutathera. AAA started commercial operations on this site in 2008. It is in Ivrea that Lutathera was developed from a radiochemic
5/23/16 - Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency
Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced it received Fast Track Designation from the U.S. Food& Drug Administration for its lead investigational molecule, AEB1102, to treat...
5/23/16 - Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
Aeolus Pharmaceuticals, Inc., a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it will be presenting at the 6 th annual LD Micro Invitational on Tuesday, June 7th at 9:00AM PDT/ 12 Noon EDT at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. Cavalier will prov
5/23/16 - Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barr Syndrome
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for Coversin for the treatment of Guillain Barr Syndrome. "We are pleased to receive this opinion from CO
5/23/16 - Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
Akebia Therapeutics, Inc., a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor, today presented positive results from a drug-drug interaction study of vadadustat, the Company s oral therapy for the treatment of anemia related to chronic kidney dise
5/23/16 - AlloSource Distributes First Bioengineered Blood Vessels For Humacyte Phase III Clinical Trial
CENTENNIAL, Colo., May 23, 2016/ PRNewswire-USNewswire/ AlloSource , one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced the distribution of investigational bioengineered blood vessels for Humacyte's Phase II
5/23/16 - Anacor Pharmaceuticals Reports First Quarter 2016 Financial Results
By a News Reporter-Staff News Editor at Pharma Business Week Anacor Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2016. In January 2016, we submitted our NDA for crisaborole topical ointment, 2%, to the FDA ahead of schedule. The FDA has accepted the crisaborole NDA for review with a PDUFA goal date of Janu
5/23/16 - ANI Announces Appointment of Mark J. Ginski Ph.D as Vice President Corticotropin Product Development
ANI Pharmaceuticals, Inc. today announced the appointment of Mark Ginski Ph.D as Vice President Corticotropin Product Development, effective May 23, 2016. Mark has held various positions in specialty drug development with Shire Pharmaceuticals, Alba Therapeutics, Cerecor Inc, Questcor Pharmaceuticals and most recently, Mallinckrodt Pharmaceutical
5/23/16 - Announcing New Episode of Innovations, Airing Saturday, May 28, 2016 via Fox Business
May 23, 2016 DMG Productions announced today the upcoming airing of Innovations with Ed Begley, Jr., scheduled to broadcast on Saturday, May 28, 2016 at 4:00 pET via Fox Business. "These advancements are changing the way we live," said Michele Nehls, Producer for the series. About Innovations& DMG Productions: Innovations, hosted by award winnin
5/23/16 - Arm of I-SPY 2 TRIAL Investigating Medivation's Talazoparib for Treatment of Breast Cancer Activated
Medivation, Inc. today announced that the talazoparib-containing arm of the I-SPY 2 TRIAL has been activated. "We are delighted that the combination of talazoparib and irinotecan was chosen to be evaluated in this innovative trial design seeking to replace components of standard chemotherapy with more targeted, potentially less toxic agents," said
5/23/16 - Aurinia Initiates First Clinical Study of Voclosporin for Japan
By a News Reporter-Staff News Editor at Clinical Trials Week Aurinia Pharmaceuticals Inc. announced that after constructive interactions with the Japanese Pharmaceuticals and Medical Devices Agency, the Company will initiate a study of voclosporin in healthy Japanese volunteers. "Japan represents a substantial market opportunity for the Company"
5/23/16 - Aurinia Reports First Quarter 2016 Financial Results and Operational Highlights
The first quarter of 2016 was highlighted by the completion of patient enrollment in our Phase 2 b clinical trial and obtaining fast track designation from the FDA for voclosporin. In addition to these clinical and regulatory successes, the Company received promising data from the open-label AURION study that further supports our hypothesis on the.
5/23/16 - Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today announced the appointment of Pete Gagnon as the company's vice president of process sciences. Prior to joining Avid, Mr. Gagnon spent 25 years as the founder and president of Validated Biosystems, an international consultancy specializing in hands-on develop
5/23/16 - Azevan Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of SRX246 in Intermittent Explosive Disorder
By a News Reporter-Staff News Editor at Clinical Trials Week Azevan Pharmaceuticals, Inc., which is developing novel small molecule medicines for disorders of stress, mood, and behavior, announced that enrollment has been completed in a Phase 2 clinical study of the company's lead compound SRX246 in adults with DSM -5 Intermittent Explosive Disor
5/23/16 - Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
*Vaccine significantly boosted antibodies and T cells against RSV in the majority of elderly subjects* Vaccine induced a broad immune responses against all RSV subtypes* Conference call and webcast today at 8:30 am EDT COPENHAGEN, Denmark, May 23, 2016- Bavarian Nordic A/S today announced positive top line results from its first-in-man Phase 1 tria
5/23/16 - Biocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests
Biocept, Inc., a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes utilizing Biocept's
5/23/16 - Biocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests [UMCI News]
Biocept, Inc. a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes utilizing Biocept's...
5/23/16 - Bracket Announces New Mobile Suite of Applications for Clinical Trials
Bracket, a leading clinical trial technology company and specialty services provider, has released a new suite of mobile applications to support pharmaceutical and biotechnology companies running clinical trials. Bracket Patient Diary TM, Bracket RTSM TM, and Bracket Analytics TM are now available for download from iTunes and Google Play.
5/23/16 - CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma FLC
By a News Reporter-Staff News Editor at Clinical Trials Week CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces that China's Food and Drug Administration has approved the Company's application to conduct a Phase 2 clinical trial in fibrolamellar..
5/23/16 - Celator Pharmaceuticals Announces First Quarter 2016 Financial Results and Business Update
By a News Reporter-Staff News Editor at Clinical Trials Week Celator Pharmaceuticals, Inc. reported business highlights and financial results for the first quarter ended March 31, 2016. "Our Phase 3 trial of VYXEOS? demonstrated a statistically significant improvement in overall survival, among other benefits, in patients with high-risk acute
5/23/16 - Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines
Most notably, there are FDA approvals for three vaccines, although two, Gardasil and Cervarix, are preemptive in nature, fighting human papillomavirus that often leads to cancer. Dendreon garnered FDA approval of Provenge in 2010 for metastatic castrate resistant prostate cancer patients who demonstrate minimal or no symptoms. In February 2015, Val
5/23/16 - ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
ChemoCentryx, Inc.,, a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced the presentation of positive results from its Phase II CLEAR trial with CCX168 in patients with anti-neutrophil cytoplasmic antibody- associated vasculitis,..
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415